The Quantellect read.As of Nov 19, 2026, 9 active firms cover Ovid Therapeutics Inc: 9 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $5.00 to $9.00, a moderate spread. The average target of $6.60 sits 193% above the current $2.25. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 7 to 9 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.10 next quarter toward $-0.40 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 active firms
Buy
Strong Buy00%
Buy9100%
Neutral00%
Sell00%
Strong Sell00%
Based on 9 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$6.60
+192.7% upside
Average target across 5 active firms as of Nov 19, 2026 vs $2.26 current
Highest Target$9.00
Average Target$6.60
Lowest Target$5.00
Detailed analyst forecasts for OVID
Showing 1–5 of 5 named analysts shown · 9 active firms in the rating projection
As of Nov 19, 2026, 9 of 9 active firms rate OVID a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
OVID EPS & revenue forecast
EPS · NEXT QUARTER
$-0.10
Range $-0.11 – $-0.07 · 9 analysts · -271% YoY
Next period, 9 analysts expect Ovid Therapeutics Inc to earn $-0.10 a share (range $-0.11 – $-0.07), versus $0.06 a year earlier. Full-year consensus is $-0.40, growing to $-0.40 the year after.
REVENUE · NEXT QUARTER
$16.7K
Range $0 – $100.0K · 9 analysts
Revenue is expected to reach $16.7K (range $0 – $100.0K). Full-year consensus is $810.5K, rising to $258.4K next year.
Top analysts covering Ovid Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on OVID.
#1
Laura Chico
Wedbush · Rank #55
Buy
$7.00+210.4% to target
Overall win rate
46%
+ Follow
#2
Marc Goodman
Leerink Partners · Rank #251
Buy
$5.00+121.7% to target
Overall win rate
46%
+ Follow
#3
Raghuram Selvaraju
HC Wainwright & Co. · Rank #423
Buy
$5.00+121.7% to target
Overall win rate
36%
+ Follow
#4
Jay Olson
Oppenheimer · Rank #484
Buy
$7.00+210.4% to target
Overall win rate
31%
+ Follow
#5
Thomas Shrader
BTIG · Rank #553
Buy
$4.00+77.4% to target
Overall win rate
32%
+ Follow
OVID stock forecast FAQ
What is OVID's average 12-month price target?+
The 5 active firms with a live target average $6.60 for Ovid Therapeutics Inc over the next 12 months, ranging from a $9.00 high to a $5.00 low, as of Nov 19, 2026.
Is OVID stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 9 active firms as of Nov 19, 2026, 9 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for OVID?+
The Street-high target is $9.00 (Oppenheimer), and the Street-low is $5.00 (HC Wainwright & Co.). The average of all 5 active-firm targets is $6.60.
How many active Wall Street firms cover OVID?+
9 active firms have a recognized rating on Ovid Therapeutics Inc as of Nov 19, 2026, and 5 active firms carry a live 12-month price target.
Who is the most accurate analyst covering OVID?+
Among analysts who currently cover OVID, Laura Chico of Wedbush has the strongest overall Quantellect track record (Rank #55). Their current call is Buy with a $7.00 target.
What is Ovid Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-0.10 per share (range $-0.11 – $-0.07) across 9 analysts. Full-year EPS is projected at $-0.40, rising to $-0.40 the following year.
How much revenue is Ovid Therapeutics Inc expected to report next quarter?+
Consensus revenue is $16.7K (range $0 – $100.0K). Full-year revenue is projected at $810.5K, growing to $258.4K next year.
Have analysts been upgrading or downgrading OVID lately?+
As of Nov 19, 2026, 9 of 9 active firms rate OVID a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their OVID calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.